10-Q: Lantern Pharma Reports Third Quarter 2024 Results, Progresses Clinical Programs

Lantern Pharma reported a net loss of $4.5 million for the third quarter of 2024, while advancing its clinical programs and research initiatives.

Summary

• Lantern Pharma reported a net loss of $4.5 million for the three months ended September 30, 2024, compared to a net loss of $3.2 million for the same period in 2023.
• The company's operating expenses totaled $5.2 million for the quarter, with research and development expenses accounting for $3.7 million.
• For the nine months ended September 30, 2024, the net loss was $14.9 million, compared to $11.8 million for the same period in 2023.
• Research and development expenses for the nine-month period were $11.9 million, a significant increase from $8.3 million in the prior year.
• The company's cash and cash equivalents stood at $8.1 million as of September 30, 2024, with total assets of $30.3 million.
• Lantern Pharma believes its current cash, cash equivalents, and marketable securities will fund operations for at least 12 months from the filing date of this report.
• The company is actively progressing clinical trials for its lead drug candidates LP-300, LP-184, and LP-284, as well as its Antibody Drug Conjugate (ADC) program.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company is making progress in its clinical programs and has sufficient funding for the next 12 months, the increasing net losses and R&D expenses are concerning. The company's reliance on future capital raises also adds uncertainty.

Positives

• The company is actively progressing its clinical trials for LP-300, LP-184, and LP-284.
• The Antibody Drug Conjugate (ADC) program is advancing in preclinical research.
• Lantern Pharma believes it has sufficient cash and marketable securities to fund operations for at least the next 12 months.
• The company has a proprietary AI platform, RADR, which is being used to streamline drug development.
• The company is exploring potential capital raises and grant funding to support its capital needs.

Negatives

• The company experienced a net loss of $4.5 million in Q3 2024, which is higher than the $3.2 million loss in Q3 2023.
• Research and development expenses have increased significantly, reaching $3.7 million in Q3 2024.
• The company's cash and cash equivalents have decreased to $8.1 million as of September 30, 2024, from $21.9 million at the end of 2023.
• The company has not generated any revenue to date, relying on equity sales for funding.

Risks

• The company is subject to intense competition, government regulation, and rapid technological change.
• The company's operations are subject to significant risks and uncertainties, including financial, operational, technological, and regulatory risks.
• The company's marketable securities may fluctuate in value due to changes in interest rates.
• The company maintains significant cash balances at financial institutions that are in excess of FDIC coverage.
• The company may need to raise additional capital in the future to fund its operations and clinical trials.
• The company's clinical trials may not be successful, and its drug candidates may not receive regulatory approval.

Future Outlook

The company believes its existing cash, cash equivalents, and marketable securities will enable it to fund operating expenses and capital expenditure requirements for at least 12 months from the date of the report. The company expects to continue to incur significant operating losses for the foreseeable future as it continues to develop its pipeline.

Management Comments

• The company plans to continue to explore periodic capital raises and also plans to apply for grant funding in the future to assist in supporting its capital needs.
• We may also explore the possibility of entering into commercial credit facilities as an additional source of liquidity.

Industry Context

Lantern Pharma is operating in the competitive and rapidly evolving biopharmaceutical industry, focusing on oncology. The company's strategy of leveraging AI and genomic data to streamline drug development aligns with the industry's increasing adoption of data-driven approaches. The company's focus on rescuing previously failed drug candidates is a unique approach in the industry.

Comparison to Industry Standards

• Lantern Pharma's approach of using AI to identify and rescue drug candidates is not common among all biopharma companies, but is a growing trend.
• The company's research and development expenses are typical for a clinical-stage biotech company, but the specific amounts vary based on the number and stage of clinical trials.
• The company's cash burn rate is consistent with other companies in the sector, but the company's ability to raise capital will be critical for its long-term success.
• Compared to companies like Allarity Therapeutics A/S, from whom they reacquired LP-100, Lantern is focusing on a more targeted approach using AI and biomarkers.
• Other companies like Actuate Therapeutics, with whom they have a collaboration, are also focused on novel cancer treatments, but Lantern's AI platform gives them a unique advantage.

Corporate Governance

Related Party Transactions

• Certain affiliates of Bios Partners beneficially own greater than 10% of the Company’s common stock and also hold substantial beneficial ownership interests in Actuate.

Stakeholder Impact

• Shareholders may be concerned about the increasing net losses and the need for future capital raises.
• Employees may be impacted by the company's financial performance and future growth prospects.
• Customers (potential patients) may benefit from the company's drug development efforts.
• Suppliers and creditors may be impacted by the company's financial stability.

Next Steps

• Continue clinical trials for LP-300, LP-184, and LP-284.
• Advance the Antibody Drug Conjugate (ADC) program.
• Explore potential capital raises and grant funding.
• Finalize and enter into the amendment to the LP-300 work order in the fourth quarter of 2024.

Key Dates

Keywords

biopharmaceutical, oncology, clinical trials, artificial intelligence, drug development, RADR platform, LP-300, LP-184, LP-284, ADC, biomarker, genomics